Follow The Filings

FTRE Fortrea Holdings Inc.

Health Care, filed as FORTREA HLDGS INC (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.6%
  • $52M
  • 1 reduce

In 2026 Q2 Corvex Management trimmed Fortrea.

Who owns this now

Largest portfolio weights among holders, up to 1.6% (Corvex Management). Not free-float ownership.

  1. Corvex Management Reduce 1.6%

Who owns FTRE

Sorted by value, long equity only, as of 2026 Q2.

History
Corvex Management 1.6%, was 1.7% Reduce −35.6% 2,988,551 $52M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FTRE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FTRE insider trades
  • None no insider bought on the open market
  • $280K sold by 3 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Machelle Sanders Director
    Sale
    $175K 9,700 shares at $18.01 21% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  2. Mark A. Morais COO
    Sale
    $79K 4,674 shares at $16.82 6.1% of stake
    Traded Jun 10 Filed Jun 12
    ↗
  3. Robert Parks Chief Accounting Officer
    Sale
    $27K 2,000 shares at $13.44 8.9% of stake
    Traded May 18 Filed May 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 21 sales to cover taxes, and 1 share withholding for taxes.

Congress

1 member of Congress traded FTRE in the last three years: 0 buys and 1 sale. 1 member listed it in 2025 annual reports.

All Congress trades
  1. J. French Hill R-AR-2Spouse Sell $1K–$15K Jun 23, 2025 filed Jul 24, 2025

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.11B $2.7B $2.72B
Net income -$3.4M -$328.5M -$986.2M
Net margin * -0.1% -12.2% -36.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.25B $0.948B $0.897B
Total non-current assets * $3.1B $2.63B $1.82B
Total assets $4.36B $3.58B $2.72B
Total current liabilities $775.9M $949.5M $913.3M
Total non-current liabilities * $1.84B $1.27B $1.24B
Total equity $1.74B $1.36B $0.564B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $167.4M $262.8M $113.5M
Cash from investing -$31.8M $251.6M $14.4M
Cash from financing -$139M -$497.8M -$76.3M
Net change in cash -$3.4M $9.9M $56.1M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.